Development of a FLIPR Assay for the Simultaneous Identification of MrgD Agonists and Antagonists from a Single Screen

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left"></td><td align="center">Structural class</td><td align="center">Percentage of confirmed hits</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Agonists</td><td align="center">Serotonergics, glutamatergics, adenosine purinergic, and Gabaergics</td><td align="center">0.6</td></tr><tr><td align="left">Antagonists</td><td align="center">Dopaminergic</td><td align="center">0.4</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Structural class of compounds obtained from LOPAC library screen that were confirmed in dose-response FLIPR assay.

BioMed Research International

tab3

Table 3

Table 3: Development of a FLIPR Assay for the Simultaneous Identification of MrgD Agonists and Antagonists from a Single Screen 